{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:11:26Z","timestamp":1790863886431,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004820","name":"Mochida Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032539","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon Richter Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:19:19Z","timestamp":1758791959000},"page":"282-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study"],"prefix":"10.1016","volume":"1","author":[{"given":"Tomoko","family":"Hasunuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Horv\u00e1t-Karajz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Dancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"K\u00f3nya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Karibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ero.2025.08.006_bib0001","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat immunol"},{"issue":"5","key":"10.1016\/j.ero.2025.08.006_bib0002","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ero.2025.08.006_bib0003","first-page":"343","article-title":"Biological therapies for rheumatoid arthritis: an overview for the clinician","volume":"15","author":"Findeisen","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.ero.2025.08.006_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.08.006_bib0005","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ero.2025.08.006_bib0006","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice","volume":"71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0007","doi-asserted-by":"crossref","first-page":"rkz010","DOI":"10.1093\/rap\/rkz010","article-title":"Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study","volume":"3","author":"Isaacs","year":"2019","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0008","first-page":"130","article-title":"Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry","volume":"42","author":"Karadag","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000340","article-title":"Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study","volume":"3","author":"Flipo","year":"2017","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ero.2025.08.006_bib0011","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Epis OM. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.ero.2025.08.006_bib0012","doi-asserted-by":"crossref","first-page":"rkac038","DOI":"10.1093\/rap\/rkac038","article-title":"Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study","volume":"6","author":"Nagy","year":"2022","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26106-0","article-title":"A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry","volume":"12","author":"Yazici","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/14397595.2014.915073","article-title":"Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts","volume":"25","author":"Matsuno","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.08.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.ero.2025.08.006_bib0016","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/annrheumdis-2015-207760","article-title":"Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.08.006_bib0017","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Review report: Actemra (tocilizumab). 2008."},{"key":"10.1016\/j.ero.2025.08.006_bib0018","unstructured":"EMA. RoActemra Summary of product characteristics [Internet]. 2022 [cited 2024 Nov 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf"},{"key":"10.1016\/j.ero.2025.08.006_bib0019","unstructured":"FDA. Actemra prescribing information [Internet]. 2013 [cited 2024 Nov 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf"},{"key":"10.1016\/j.ero.2025.08.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"issue":"3","key":"10.1016\/j.ero.2025.08.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.5429","article-title":"Patient out-of-pocket costs for biologic drugs after biosimilar competition","volume":"5","author":"Feng","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ero.2025.08.006_bib0022","article-title":"Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain","author":"P\u00e9rez-Ruiz","year":"2024","journal-title":"Farm Hosp"},{"key":"10.1016\/j.ero.2025.08.006_bib0023","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1136\/annrheumdis-2024-eular.651","article-title":"Budget impact analysis of a tocilizumab biosimilar: a UK payer perspective","volume":"83","author":"Shastri","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.08.006_bib0024","doi-asserted-by":"crossref","unstructured":"Emery P, Choy E, Hasunuma T, Okada M, Polgari Z, Horv\u00e1t-Karajz K, et al., Pharmacokinetic, pharmacodynamic, safety and immunogenicity evaluation of the proposed tocilizumab biosimilar RGB-19 subcutaneously administered to healthy male participants: a Phase 1, randomised, single-dose cross-over study. Barcelona: European Congress of Rheumatology (EULAR); 2025.(Abstract: 1398).","DOI":"10.1016\/j.ard.2025.06.1521"},{"issue":"5","key":"10.1016\/j.ero.2025.08.006_bib0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40259-025-00734-0","article-title":"Comprehensive physico-chemical and functional similarity assessment of intravenous and subcutaneous RGB-19 drug products as proposed biosimilars to tocilizumab reference product","volume":"39","author":"Solti","year":"2025","journal-title":"Biodrugs"},{"key":"10.1016\/j.ero.2025.08.006_bib0027","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product [Internet]. 2016 [cited 2025 Jan 31]. Available from: https:\/\/www.fda.gov\/media\/70958\/download"},{"key":"10.1016\/j.ero.2025.08.006_bib0028","unstructured":"EMA. Guideline on the investigation of bioequivalence [Internet]. 2010 [cited 2025 Jan 31]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf"},{"key":"10.1016\/j.ero.2025.08.006_bib0029","unstructured":"Division of Drugs, National Institute of Health Sciences. Guideline for Bioequivalence Studies of Generic Products [Internet]. 2020 [cited 2025 Mar 4]. http:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/Generic\/GL-E_120229_BE.pdf"},{"issue":"4","key":"10.1016\/j.ero.2025.08.006_bib0030","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2025.08.006_bib0031","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-021-00304-0","article-title":"Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study","volume":"8","author":"Pierini","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ero.2025.08.006_bib0032","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/1744666X.2025.2451215","article-title":"Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study","volume":"21","author":"Burmester","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.ero.2025.08.006_bib0033","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13543784.2023.2212155","article-title":"Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study","volume":"32","author":"Yu","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.ero.2025.08.006_bib0034","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.08.006_bib0035","unstructured":"Biogen. TOFIDENCE\u2122 (tocilizumab), a Biosimilar Referencing ROACTEMRA\u00ae, Approved in the European Union [Internet]. 2024 [cited 2025 Jan 30]. Available from:https:\/\/investors.biogen.com\/news-releases\/news-release-details\/tofidencetm-tocilizumab-biosimilar-referencing-roactemrar"}],"updated-by":[{"DOI":"10.1016\/j.ero.2026.100242","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:47:07Z","timestamp":1763308027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S3050708125000692"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.08.006","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}